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Abstract
Background: The tumor suppressor gene p53 is involved in multiple cellular pathways including apoptosis,
transcriptional control, and cell cycle regulation. In the last decade it has been demonstrated that the single
nucleotide polymorphism (SNP) at codon 72 of the p53 gene is associated with the risk for development of various
neoplasms. MDM2 SNP309 is a single nucleotide T to G polymorphism located in the MDM2 gene promoter. From
the time that this well-characterized functional polymorphism was identified, a variety of case-control studies have
been published that investigate the possible association between MDM2 SNP309 and cancer risk. However, the
results of the published studies, as well as the subsequent meta-analyses, remain contradictory.
Methods: To investigate whether currently published epidemiological studies can clarify the potential interaction
between MDM2 SNP309 and the functional genetic variant in p53 codon72 (Arg72Pro) and p53 mutation status, we
performed a meta-analysis of the risk estimate on 27,813 cases with various tumor types and 30,295 controls.
Results: The data we reviewed indicated that variant homozygote 309GG and heterozygote 309TG were
associated with a significant increased risk of all tumor types (homozygote comparison: odds ratio (OR) = 1.25, 95%
confidence interval (CI) = 1.13-1.37; heterozygote comparison: OR = 1.10, 95% CI = 1.03-1.17). We also found that
the combination of GG and Pro/Pro, TG and Pro/Pro, GG and Arg/Arg significantly increased the risk of cancer (OR
= 3.38, 95% CI = 1.77-6.47; OR = 1.88, 95% CI = 1.26-2.81; OR = 1.96, 95% CI = 1.01-3.78, respectively). In a stratified
analysis by tumor location, we also found a significant increased risk in brain, liver, stomach and uterus cancer (OR
= 1.47, 95% CI = 1.06-2.03; OR = 2.24, 95%CI = 1.57-3.18; OR = 1.54, 95%CI = 1.04-2.29; OR = 1.34, 95%CI = 1.07-
1.29, respectively). However, no association was seen between MDM2 SNP309 and tumor susceptibility in the
stratified analysis by p53 mutation status (GG vs TT: OR = 1.17, 95% CI = 0.75-1.82 and TG vs TT: OR = 1.09, 95% CI
= 0.89-1.34 for positive p53 mutation status; GG vs TT: OR = 0.95, 95% CI = 0.72-1.25 and TG vs TT: OR = 1.06, 95%
CI = 0.85-1.30 for negative p53 mutation status).
Conclusions: The analyses indicate that MDM2 SNP309 serves as a tumor susceptibility marker, and that there is an
association between MDM2 SNP309 and p53 Arg72Pro regarding tumor susceptibility. Further studies that take into
consideration environmental stresses and functional genetic variants in the p53-MDM2-related genes are warranted.
Background
The p53 protein is a principal mediator of growth arrest,
apoptosis, and senescence in response to an array of cel-
lular damage [1-3]. Various types of stress can induce
high levels of p53 protein, thus preventing inappropriate
propagation of stressed cells. Because of this protein’s
vital role in maintaining normal cellular function, tumor
cells have developed numerous methods to disable its
function. Indeed, the p53 protein is inactivated by muta-
tions or deletions in approximately 50% of human can-
cers [4]. A polymorphism at codon 72 with a single-base
change in the p53 gene causes an amino acid replace-
ment in the transaction domain of the protein Arg
(CGC) with Pro (CCC). Although the functional differ-
ences of these two variants of the p53 protein remain
unclear, it has been demonstrated that a single nucleo-
tide polymorphism (SNP) at codon 72 of the p53 gene
is associated with the risk for development of various
neoplasms. However, in the rest of human tumor types,
the p53 gene remains in a wild-type form and its activity
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any medium, provided the original work is properly cited.is eradicated by its principal cellular inhibitor, murine
double minute 2 protein (MDM2) [5].
MDM2 is the primary regulator of p53. MDM2 and
p53 regulate each other through a feedback loop. In
this mechanism, p53 induces MDM2, and MDM2 then
acts as an E3 ubiquitin ligase that exports p53 out of
the nucleus and promotes its degradation [6]. More-
over, MDM2 is capable of affecting genome stability in
a p53-independent way [7]. A functional single-nucleo-
tide T to G polymorphism is present in the promoter
of the MDM2 gene (rs2279744), known as MDM2
SNP309[8]. Bond et al. demonstrated that the GG gen-
otype of SNP309 enhanced the affinity of the transcrip-
tion factor Sp1 to the MDM2 promoter in cell lines,
and consequently enhanced the expression of MDM2
RNA and protein, resulting in a possible attenuation of
the p53 pathway [9]. In both patients with hereditary
Li-Fraumeni syndrome (one p53 allele mutated) and
patients with sporadic soft tissue sarcoma, the presence
of the SNP309 G-allele accelerated tumor formation
[10,11].
To date, a number of studies have explored the asso-
ciation between MDM2 SNP309 and the risk of various
types of cancer [12-77], including brain, breast, colorec-
tal, hepatocellular, lung, ovar i a n ,g a s t r i c ,u t e r u s ,a n ds o
on. Nearly three years since the meta-analysis was per-
formed by Hu et al. [78], forty-one additional case-con-
trol studies regarding the association between SNP309
and tumor risk have appeared, which is a greater num-
ber of studies than the number of studies included in
the original meta-analysis. Therefore, an updated meta-
analysis is needed. The meta-analysis presented in this
study aims to assess whether MDM2 SNP309 is asso-
ciated with cancer risk and to investigate the possible
interaction between MDM2 SNP309 and p53 mutation
status and the p53 codon72 polymorphism.
Methods
Primary search strategy
We searched the Pub Med and CNKI databases for all
genetic association studies published to date on the
MDM2 SNP309 and tumor risk (the most recent
search update was April 2, 2010). To perform the
search we used the subject terms “MDM2 polymorph-
ism(s) and tumor”. Only English-language and Chi-
nese-language papers were included. The references
cited in the original studies or review articles concern-
ing the relevant topic were retrieved in order to poten-
tially broaden the search with additional relevant
publications.
Criteria for study inclusion and exclusion
All studies reporting human associations that met the
following criteria, regardless of sample size, were
included in this meta analysis; if not, the studies were
excluded: (a) the study is a case-control study on the
association of MDM2 SNP309 and tumor susceptibility;
(b) the study reports genotypic frequencies of MDM2
SNP309 in cancer patients and controls; (c) the geno-
type of the control population is in Hardy-Weinberg
equilibrium. If the study had the same population
resource or had overlapping subjects, only the study
reporting the largest population was selected. Hence, we
included sixty-six studies in our meta-analysis, contain-
ing 27,813 cases with different tumor types and 30,295
controls.
Data extraction
Two reviewers independently extracted data using a
standardized extraction form. For each case, if a dispar-
ity was identified the two reviewers debated until a con-
sensus was reached on all items. The following
information was collected from each publication: the
first author’s name, year of publication, tumor type, eth-
nicity, genotype frequency for cases and controls, minor
allele frequency (MAF) in controls, p53 mutation status,
and interaction with p53 Arg72Pro status (Additional
file 1). If a study contained more than one tumor type
or ethnicity, genotype data were extracted separately
according to tumor type or ethnicity for subgroup ana-
lyses. Racial descent was classified as European, Asian,
African, and mixed.
Statistical analysis
Odds ratios (ORs) were pooled to evaluate the associa-
tion between MDM2 SNP309 and tumor risk. The fixed
effect model and the random effect model based on the
Mantel-Haenszel method and the Dersimonian and
Laird method, respectively, were used to pool data from
different studies. If the heterogeneity between studies is
absent, these two models provide similar results; other-
wise, it is more appropriate to adopt the random effect
model. We first compared the tumor risk in the variant
homozygote GG and in the heterozygote TG with the
wild-type TT homozygote. The ORs and 95% CIs were
calculated. The statistical significance of the OR was
determined using the Z test. Statistical heterogeneity
between studies was assessed with the c
2-based Q test
and Ι
2, heterogeneity was considered significant when P
< 0.1, and Ι
2 was used to qualify variation in OR attribu-
table to heterogeneity. Crossover analysis was used for
interaction analysis.
Publication bias was investigated using the funnel plot,
a method used to analyze subjective data. To supple-
ment the funnel plot method, we also adopted the liner
regression approach proposed by Egger et al. ORs and
95%CIs were generated by meta-analysis using STATA
(version 10.0).
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Characteristics of studies
After screening the titles and abstracts, a total of eighty-
two full text articles were reviewed to identify eligibility
for our systematic review. According to the inclusion cri-
teria, we found that five articles were meta-analyses
[78-82], two studies utilized the same population
resource or contained overlapping subjects, nine articles
did not include controls, and for two studies we were
unable to extract the data. In addition, we included two
studies [23,35] that were retrieved manually from the ori-
ginal articles’ references. Thus, for our systematic-review,
we summarized the results of sixty-six case-control stu-
dies [12-77], including sixty-three English language arti-
cles and three Chinese language articles [36,39,57] and
containing seventy-eight comparisons (Figure 1).
The detailed characteristics of the sixty-six case-con-
trol studies are shown in Additional file 1. These studies
contain thirty tumor types, and the racial descent of the
subjects is classified as European, Asian, African, and
mixed. The genotype distribution observed in the con-
trols was consistent with the Hardy-Weinberg equili-
brium for all studies. There were ten studies in which
the p53 mutation status was detected in tumor cases,
but only seven of these studies presented the MDM2
SNP309 genotype distributions according to p53
mutation status [16,20,35,37,41,54,70]. There were
twelve studies that investigated the interaction of
MDM2 SNP309 and p53 codon72 polymorphism on
cancer risk; however, only six studies [19,28,46,51,60,72]
offered detailed data (Table 1).
Quantitative synthesis
There was wide variation in the MDM2 309G allele fre-
quency in the different ethnic groups (Additional file 1).
The mean frequency of the G allele was 0.11 for Afri-
can, 0.37 for European, 0.50 for Asian, and 0.36 for
mixed ethnicities.
When all of the eligible studies were pooled, we found
that the variant genotypes were associated with increased
tumor risk in several genetic models. The variant homo-
zygote GG exhibited a significantly increased risk for all
tumor types when compared with the wild-type TT
homozygote (OR = 1.25, 95%CI = 1.13-1.37; P < 0.001 for
heterogeneity test; Ι
2 = 66.9% for heterogeneity). Interest-
ingly, we also found that the variant heterozygote TG
exhibited an increased risk for all tumor types (OR =
1.10, 95%CI = 1.03-1.17; P < 0.001 for heterogeneity test;
Ι
2 = 51.7% for heterogeneity). Significant effects were also
found both in the recessive and dominant models (reces-
sive model: OR = 1.18, 95%CI = 1.10-1.27; P < 0.001 for
heterogeneity test; Ι
2 = 55.1% for heterogeneity; dominant
models: OR = 1.14, 95%CI = 1.07-1.22; P < 0.001 for het-
erogeneity test; Ι
2 = 62.2% for heterogeneity; Table 2).
Subsequently, we investigated the effects of MDM2
SNP309 stratified by tumor location, ethnicity, and p53
mutation status. We found that there was an association
between individuals with the GG genotype or TG geno-
type and an elevated risk of breast, brain, liver, stomach,
and uterus cancer when compared to subjects with the
TT genotype (Table 2). Interestingly, the risk was signifi-
cant in brain, liver, and stomach cancer. Regarding the
different ethnic groups, we found a subtle cancer risk in
the European population (OR = 1.13, 95%CI = 1.01-1.25)
and a significant cancer risk in the Asian population (OR
= 1.36, 95%CI = 1.18-1.56). However, no significant asso-
ciations were found in either the p53 mutation-positive
or p53 mutation-negative subgroup (Table 2).
Figure 1 Flow chart of the eligible study selection process.
Table 1 Datas for the interaction of p53 codon72 polymorphism and MDM2 SNP309 for tumor susceptibility
First author Tumor site 309TT 309TG 309GG
(reference ) Case* Control* Case* Control* Case* Control*
Yang M GCA 19/61/27 96/150/52 59/119/72 162/222/114 45/65/33 58/114/32
Singh V BC 10/11/4 4/18/3 23/21/4 13/32/2 13/13/5 11/15/7
Yoon YJ HCC 23/18/4 40/38/6 48/58/19 56/53/23 39/35/43 28/45/8
Xiong XJ AML 6/22/4 12/17/6 29/62/32 22/33/13 17/43/16 5/14/6
Zhang X LC 62/127/60 122/222/74 170/259/132 223/343/145 89/120/87 80/166/45
Cox DG BC 349/218/40 488/346/60 317/266/45 539/365/52 104/63/14 166/92/10
*P53 codon72 wild-type homozygote/heterozygote/variant homozygote
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In this meta-analysis, we pooled the eligible studies for
association of MDM2 SNP309 and p53 Arg72Pro on
tumor risk. In comparison to the reference MDM2
309TT and p53 Arg/Arg genotype, the OR (3.38) for
subjects with the MDM2 309GG and p53 Pro/Pro geno-
type is larger than the OR (1.96) for subjects with the
MDM2 309GG and p53 Arg/Arg or the OR (1.38) for
subjects with the MDM2 309TT and p53 Pro/Pro geno-
type (Table 3). These results indicate a possible com-
pounding effect between the MDM2 309GG and p53
Pro/Pro genotype that leads to a significantly increased
risk of cancer. The p-value for the overall interaction
analysis is less than 0.001.
Table 2 Summary OR (95%CI) and I-squre for various contrasts of the MDM2 SNP309 polymorphism and tumor risk
Subgroup No.
comparisons
TG vs. TT GG vs. TT GG vs. TT/TG GG/TG vs. TT
OR (95% CI) I-squre
(%)
OR (95% CI) I-squre
(%)
OR (95% CI) I-squre
(%)
OR (95% CI) I-squre
(%)
Total 78 1.10* (1.03-1.17) 51.7 1.25* (1.13-1.37) 66.9 1.18* (1.10-
1.27)
55.1 1.14* (1.07-1.22) 62.2
Tumor site
Breast 18 1.09* (1.00-1.19) 12.8 1.09 (0.96-1.24) 20.7 1.05 (0.94-1.17) 19.5 1.09* (1.01-1.17) 9.1
Lung 10 1.06 (0.93-1.22) 64.8 1.21 (0.99-1.47) 67.8 1.12 (0.99-1.27) 42.7 1.10 (0.95-1.27) 72.4
Ovarian 3 0.85 (0.63-1.16) 25.2 0.79 (0.48-1.28) 52.3 0.89 (0.63-1.25) 33.1 0.82 (0.57-1.18) 50.5
Pancreatic 2 1.55 (0.98-2.46) 59 1.56 (0.66-3.68) 74.6 1.24 (0.68-2.24) 56.4 1.54 (0.90-2.65) 73
Blood 4 1.08 (0.65-1.79) 79.4 1.11 (0.57-2.17) 80.3 1.09 (0.71-1.68) 63.8 1.10 (0.67-1.82) 81.6
Brain 5 1.47* (1.06-2.03) 57.6 1.18* (1.08-3.03) 69.5 1.38 (0.94-2.01) 55.9 1.51* (1.10-2.07) 61.3
Colorectal 6 1.14 (0.89-1.47) 51.2 1.05 (0.65-1.68) 74.4 1.00 (0.67-1.49) 70 1.13 (0.85-1.50) 65.5
Esophageal 2 1.11 (0.86-1.43) 36 1.26 (0.92-1.72) 51.2 1.28 (0.97-1.69) 63.1 1.18 (1.00-1.41) 0
Head-neck 4 0.92 (0.67-1.28) 71.6 1.01 (0.69-1.47) 72.3 1.11 (0.96-1.29) 1.7 0.94 (0.67-1.34) 77.8
Liver 4 1.57* (1.18-2.09) 0 2.24*(1.57-3.18) 0 1.65* (1.25-
2.17)
0 1.76* (1.34-2.31) 0
Skin 4 1.00 (0.86-1.16) 0.4 1.05 (0.85-1.29) 1.2 1.05 (0.86-1.27) 0 1.01 (0.86-1.19) 26.6
Stomach 5 1.03 (0.75-1.42) 72.2 1.54* (1.04-2.29) 76.4 1.49* (1.20-
1.84)
53.2 1.18 (0.84-1.65) 77.6
Uterus 8 0.95 (0.81-1.11) 0 1.34* (1.07-1.69) 5.3 1.26 (0.92-1.72) 51.2 0.81* (0.70-0.94) 0
Other 3 0.98 (0.72-1.32) 14.6 1.14 (0.63-2.08) 66.8 1.16 (0.72-1.85) 62.6 1.02 (0.67-1.52) 55
Racial
descent
African 3 1.22 (0.80-1.86) 61.2 0.75 (0.40-1.41) 0 0.73 (0.39-1.36) 0 1.16 (0.80-1.70) 56
European 34 1.05 (0.98-1.13) 34.8 1.13* (1.01-1.25) 40.8 1.10* (1.00-
1.20)
30.8 1.08* (1.00-1.16) 42.1
Asian 32 1.11 (0.99-1.24) 58.4 1.36* (1.18-1.56) 68.6 1.27* (1.15-
1.40)
58.6 1.18* (1.05-1.32) 65.8
Mixed 9 1.10 (0.91-1.32) 49.7 1.16 (0.86-1.56) 59.6 1.08 (0.88-1.35) 37.3 1.10 (0.92-1.32) 52.7
p53 mutation
status
Positive 7 1.09 (0.89-1.34) 0 1.17 (0.75-1.82) 59.4 1.09 (0.70-1.69) 70.3 1.12 (0.92-1.36) 0
Negative 7 1.06 (0.85-1.30) 4.1 0.95 (0.72-1.25) 0 0.97 (0.76-1.22) 0 1.03 (0.85-1.25) 0
*P value < 0.05 for significance tests of OR = 1
‡ P value = 0.056 for significance test of OR = 1
Table 3 Interaction of MDM2 SNP309 (T to G) and p53
Arg72Pro on tumor risk
MDM2 309T > G P53 72Arg > Pro Case Control OR (95% CI)
TT Arg/Arg 469 762 Reference
TT Arg/Pro 457 791 1.09 (0.74-1.61)
TT Pro/Pro 139 201 1.38 (0.92-2.06)
TG Arg/Arg 646 1015 1.32 (0.88-1.98)
TG Arg/Pro 785 1048 1.51 (0.96-2.38)
TG Pro/Pro 304 349 1.88 (1.26-2.81)*
GG Arg/Arg 307 348 1.96 (1.01-3.78)*
GG Arg/Pro 339 446 1.53 (0.92-2.53)
GG Pro/Pro 198 108 3.38 (1.77-6.47)*
*P values < 0.05 for significance test of OR = 1
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We observed heterogeneity between studies regarding
both overall comparisons and subgroup analyses. Hence,
the random effect model based on the Mantel-Haenszel
method was adopted for this meta-analysis. The details
of Ι
2 for each comparison are shown in Table 2.
Publication bias
The publication bias of the studies was determined by
the Funnel plot and Egger’st e s t .A ss h o w ni nF i g u r e2
(A/B/C/D), the shapes of the funnel plots appeared sym-
metrical in all comparisons, indicating the absence of
publication bias. Next, we used Egger’st e s tt op r o v i d e
statistical evidence for the funnel plot symmetry. The
greater the intercept deviation from zero in linear
regression analysis, the greater the possibility for asym-
metry. We considered the funnel plot to be symmetrical
if we observed a 95% confidence interval with an inter-
cept of zero. The results are shown in Table 4.
Discussion
On the basis of sixty-six case-control studies focused on
MDM2 309 T/G polymorphism and tumor risk, our
meta-analysis provided evidence that the variant homo-
zygote GG and heterozygote TG were significantly asso-
ciated with increased tumor risk. Our findings are in
concordance with the meta-analysis conducted by Hu et
al. which suggests that the MDM2 SNP309 serves as a
low-penetrance susceptibility tumor marker [78].
When stratified according to ethnicity, our meta-ana-
lysis showed that the GG genotype was significantly
associated with tumor risk in the Asian and European
populations. According to some previously reported stu-
dies, the GG genotype is significantly associated with
tumor risk in the Asian population, but not in the Eur-
opean population [19,80,82]. One possible reason is that
our meta-analysis includes thirty-four European study
Table 4 The results of egger’s test for four comparisons
Comparison
type
Intercept
value
t-
value
P-
value
95% CI of intercept
value
TG vs. TT 0.24 0.67 0.507 -0.49 ~ 0.98
GG vs. TT -0.07 -0.16 0.87 -0.91 ~ 0.77
GG vs. TT/TG -0.22 -0.6 0.55 -0.94 ~ 0.51
GG/TG vs. TT 0.35 0.87 0.39 -0.45 ~ 1.15
Figure 2 Funnel plot of association between MDM2 SNP309 and cancer risk.
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to previously reported comparisons. Consistent with
previously reported studies, no significant associations
were found in the African ethnic group [78]. This may
suggest a potential role for ethnic differences in genetic
b a c k g r o u n d sa sw e l la se n v i r o n m e n t a le x p o s u r e s .T h e
mean MAF in the African group was 0.10, whereas in
the Asian and European groups it was 0.50 and 0.38,
respectively. The large differences in the MAF between
the African group and the Asian or European group
may be a result of natural selection pressures, or balance
due to other related genetic variants. Therefore, further
studies regarding the MDM2 309T/G polymorphism in
Africans and the underlying mechanism for ethnic dif-
ferences are warranted.
In our meta-analysis, we included approximately thirty
tumor types stratified into fourteen subgroups according
to tumor location. In the subgroup analyses, we found a
significant association in breast cancer but a non-signifi-
cant association in lung cancer and colorectal cancer.
Interestingly, our meta-analysis determined a significant
association in brain, liver, stomach, and uterus cancer.
The ORs for the GG genotype compared to TT was
1.18, 2.24, 1.54, and 1.34, respectively. Similar findings
have been reported in previous studies, including hepa-
tocellular carcinoma associated with chronic hepatitis C,
gastric carcinoma, and sporadic endometrial carcinoma
[49,70,75], suggesting an interaction of MDM2 SNP309,
infectious factor, and hormone factor.
In order to incorporate the p53 mutation status while
investigating the effect of MDM2 SNP309 on tumors, we
included seven studies to pool the patient genotypes
according to the p53 mutations [16,20,21,35,37,41,54,70].
However, we found no discrepancy between the two p53
mutation groups, possibly due to insufficient statistical
power. Furthermore, the functional polymorphism of the
p53 codon 72 (Arg72Pro) had been shown to interact
with SNP309 in the carcinogenesis of several carcinomas
[46,51,60,72]. Our meta-analysis included six studies that
explored interaction effects between p53 Arg72Pro and
MDM2 SNP309. We found that the OR for subjects with
the MDM2 309 GG genotype and p53 72 Pro/Pro geno-
types compared to subjects with MDM2 309 TT and p53
72Arg/Arg genotypes (3.38) was larger than the OR for
subjects with the MDM2 309GG genotype and p53
72Arg/Arg (1.96) or the OR for those with MDM2
309TT and p53 72 Pro/Pro (1.38). These results sug-
gested a possible interaction effect between the MDM2
309GG and the p53 72 Pro/Pro genotype in increasing
the risk of carcinogenesis.
The strength of our meta-analysis is due to the large
number of comparisons included. However, our study
does have a limitation: the controls in the studies
included were not uniformly defined and thus the
results presented here are based upon unadjusted esti-
mates. A more precise analysis could be conducted with
estimates adjusted according to covariates such as age,
smoking, lifestyle, and environmental factors.
Conclusions
In summary, our results provide some support for the
hypothesis that MDM2 SNP309 is associated with tumor
risk and support the potential interaction effect between
the MDM2 SNP309 and the polymorphism of p53
codon72. This investigation could be extended in future
studies by incorporating other potential risk factors and
p53-MDM2-related genes for tumor development.
Additional material
Additional file 1: Characteristics of included studies investigating
the association between MDM2 SNP309 and tumor risk.
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